A Lesson Learned?

A Lesson Learned?

Roche has announced they plan to launch their new CGM in Europe thus entering a market dominated by Dexcom and Abbott. While we don’t hold out much hope that the product will have much of an impact. There is a lesson to be learned here.

First let’s be very clear here Roche is using this new toy as bait. The goal isn’t to become a major player in CGM, the goal is to sell their diabetes unit to a greater fool. After years of watching the BGM market collapse combined with their failed attempts to . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.